



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,013	06/15/2006	Julia Adam-Worrall	2003.807US	6111
67706	7590	01/08/2008	EXAMINER	
ORGANON USA, INC. PATENT DEPARTMENT 56 LIVINGSTON AVENUE ROSELAND, NJ 07068				BERNHARDT, EMILY B
ART UNIT		PAPER NUMBER		
1624				
MAIL DATE		DELIVERY MODE		
01/08/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/583,013	ADAM-WORRALL, JULIA
	<b>Examiner</b>	<b>Art Unit</b>
	Emily Bernhardt	1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_\_.  
 2a) This action is FINAL.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-4,6 and 8-12 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_ is/are allowed.  
 6) Claim(s) 1-4,6 and 8-12 is/are rejected.  
 7) Claim(s) \_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | Paper No(s)/Mail Date. _____ .                                    |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>8/14/06 &amp; 4/2/07</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application |
|   | 6) <input type="checkbox"/> Other: _____                          |

Claims 1-4,6,8-9,11 and 12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

1. There is no material difference in scope seen for reciting R6 form rings with R7 and then on the next line stating R7 form rings with R6. If applicants disagree they should point out the difference in scope. Otherwise one of the phrases should be deleted.

2. Claim 12 is of indeterminate scope for more than one reason. How does one determine who is in need and who is not of “activating a cannabinoid CB1 receptor”? One may have no visible symptoms and still be in need. It may turn out with further research that everyone is in need . Defining a disease(s) by its (their) underlying cause renders the scope of intended uses indeterminate since the claim language may read on diseases not yet known to be caused by or affected by such action or in ways not yet understood. Additionally, determining whether a given disease responds or not to activation of CB1 receptors involves much experimentation since a negative response from one patient does not mean the drug isn't useful as no drug has 100% effectiveness. Thus what “success rate” determines if a

particular compound is effective and how many patients (and dosage regimens) need to be tested? The test for determining compliance with 35 USC 112, par. two is whether applicants have clearly defined “their” invention not what may be discovered by future research as this type of claim language clearly requires.

Claims 1-4, 6, 8-12 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for unfused piperazines, does not reasonably provide enablement for fused piperazines. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and thus use the invention commensurate in scope with these claims.

1. Starting material sources for ortho-fused piperazines resulting from the joining of R6/R7 groups are not seen but are required. Specification is silent as to the availability of necessary reactants needed to prepare such ring systems or if they are commercially available. Note In re Howarth 210 USPQ 689; Ex parte Moersch 104 USPQ 122 for the need to show starting material sources commensurate with the claims' scope.
2. As there are no such fused compounds that have been made corresponding to the instant scope there is no reasonable basis for

assuming that the myriad of compounds embraced by the all the generic claims will all share the same physiological properties since they are so structurally dissimilar as to be chemically non-equivalent and there is no basis in the prior art for assuming the same. Note *In re Surrey* 151 USPQ 724 regarding sufficiency of disclosure for a Markush group. Also see MPEP 2164.03 for enablement requirements in cases directed to structure-sensitive arts such as the pharmaceutical art.

Also note the criteria for enablement as set out in *In re Wands* cited in MPEP 2164.01(a), August 2000 edition, which includes factors such as:

- 1) Breadth of the claims- the claims cover compounds easily in the millions in view of the varying variables permitted at all R variables and X;
- 2) Level of unpredictability in the art- the invention is pharmaceutical in nature as it involves binding to cannabinoid (CB1) receptors. It is well established that “the scope of enablement varies inversely with the degree of unpredictability of the factors involved” and physiological activity is generally considered to be unpredictable. See *In re Fisher* 166 USPQ 18;
- 3) Direction or guidance- the compounds made are not representative of the instant scope but are always unfused piperazines;

4) State of the prior art- The compounds are further fused indolo derivatives with a carbonyl piperazine located at the 3-position of ring system. There are no such compounds having this feature and thus no prior art evidence that the many structural permutations permitted in the instant scope are known for at least one use in the prior art;

5) Working examples- Actual test data has been presented but it is directed to unfused piperazines and thus no clear evaluation of how further fusion might affect potency to a large or small degree.

In view of the above considerations, this rejection is being applied.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emily Bernhardt whose telephone number is 571-272-0664.

If attempts to reach the examiner by telephone are unsuccessful, the acting supervisor for AU 1624, James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Emily Bernhardt/  
Primary Examiner, Art Unit  
1624

Application/Control Number: 10/583,013  
Art Unit: 1624

Page 7